Press Release: Sanofi and Novavax announce co-exclusive licensing agreement to co-commercialize COVID-19 vaccine and develop novel flu-COVID-19 combination vaccines
Go back to Press Release: Sanofi and Novavax announce co-exclusive licensing agreement to co-commercialize COVID-19 vaccine and develop novel flu-COVID-19 combination vaccines| Novavax, Inc. (NASDAQ: NVAX) | Delayed: 10.63 +0.03 (0.28%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $10.60 | 52 Week High | $9.23 | |||
| Open | $10.62 | 52 Week Low | $1.16 | |||
| Day High | $10.79 | P/E | N/A | |||
| Day Low | $10.34 | EPS | $-0.30 | |||
| Volume | 3,910,064 | |||||
